Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial
MWN-AI** Summary
Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company focused on developing innovative therapies for neurodegenerative diseases, has announced its upcoming webinar titled “Inside the Evolving ALS Landscape: Biology, Innovation, and Clinical Progress.” Scheduled for February 17, 2026, at 3:00 p.m. ET, the event aims to delve into the progression of drug development for Amyotrophic Lateral Sclerosis (ALS) and the current patient landscape.
The webinar will feature prominent medical experts, including Fred Grossman, D.O., FAPA, who will moderate the session. He will be joined by Stanley Appel, M.D., a leading neurologist and Chairman of Coya's Scientific Advisory Board, along with James Berry, M.D., MPH, Director of the Multidisciplinary ALS Clinic at Massachusetts General Hospital. This distinguished panel will discuss recent advancements in ALS treatments, the underlying biology of the disease, and ongoing challenges faced by patients and researchers.
One of the focal points of the discussion will be Coya’s novel immunotherapy, COYA 302, which is built on a combination therapy designed to enhance the function of regulatory T cells (Tregs) and reduce neuroinflammation. The webinar will also provide insights into the ongoing ALSTARS Phase 2 clinical trial examining the safety and efficacy of COYA 302.
Coya Therapeutics is dedicated to addressing systemic inflammation through its proprietary treatments, particularly for conditions like ALS where Treg dysfunction contributes to disease progression. Attendees will have the opportunity to engage in a Q&A, and a recording of the session will be made available on the Coya Therapeutics website post-event. Pre-registration for the webinar is currently open.
MWN-AI** Analysis
Coya Therapeutics, Inc. (NASDAQ: COYA) is poised at a crucial juncture in the biotechnology sector, focusing on therapies for Amyotrophic Lateral Sclerosis (ALS). The upcoming webinar on February 17, 2026, titled "Inside the Evolving ALS Landscape: Biology, Innovation, and Clinical Progress," led by renowned experts, will be pivotal in discussing advancements in ALS treatment and the patient landscape.
Investors should pay close attention to Coya’s innovative immunotherapy approach, particularly its investigational product, COYA 302, aimed at enhancing regulatory T-cell function. This mechanism has the potential to address inflammation in neurodegenerative diseases, a significant component of ALS pathology. The inclusion of key opinion leaders like Fred Grossman, D.O., and Stanley Appel, M.D., lends credence to the scientific merit of Coya's initiatives and could positively influence market perception.
The ALSTARS Phase 2 clinical trial represents a critical benchmark for Coya. Updates from this trial will be a substantial mover of the stock price, as successful results can affirm the efficacy and safety of COYA 302. Investors should tune into the webinar not just for insights but also for potential market sentiment shifts.
With the biotechnology sector being both volatile and driven by clinical data, it's essential to remain vigilant of the outcomes from ongoing trials. The company's emphasis on treating systemic inflammation through Treg modulation positions it uniquely within a burgeoning market with unmet needs.
Therefore, while Coya Therapeutics presents opportunities, prudent investors should weigh the risks associated with biotechnology investments, including regulatory hurdles and competition. A well-informed approach, leveraging insights from the upcoming webinar, can enhance decision-making in this promising but uncertain sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
? Virtual Webinar on Tuesday, Feb. 17 at 3 p.m. ET / 12 p.m. PT
? Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.; and James Berry, M.D., MPH — accomplished physicians specializing in neurological disorders
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorder, today announced it will host a live webinar on February 17, 2026 at 3:00 p.m. ET/ 12:00 p.m. PT exploring the evolving ALS treatment landscape.
Titled ‘Inside the Evolving ALS Landscape: Biology, Innovation, and Clinical Progress’ , the webinar will explore recent breakthroughs and ongoing challenges in the ALS landscape, including the biological drivers of disease and how advances in drug development are improving the patient experience, while underscoring where significant gaps remain. The discussion will highlight Coya’s novel immunotherapy approach for treating ALS, including the scientific rationale behind its combination therapy COYA 302 and will feature an overview of the Company’s ALSTARS Phase 2 clinical trial , including its design and enrollment information.
Fred Grossman, D.O., FAPA , President and Chief Medical Officer of Coya Therapeutics, will serve as the moderator for the webinar. He will be joined by the following participants:
- Stanley Appel, M.D. – Chairman, Scientific Advisory Board, Coya Therapeutics; Professor of Neurology, Houston Methodist
- James Berry, M.D., MPH – Director, Massachusetts General Hospital Multidisciplinary ALS Clinic
Webinar Information
Pre-registration is now open HERE
Date : February 17, 2026
Time : 3 p.m. ET / 12 p.m. PT
Attendees may ask questions via written Q&A. A recording of the event will be posted to the Coya Therapeutics website .
About Coya Therapeutics, Inc.
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases. This cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.
Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
For more information about Coya, please visit www.coyatherapeutics.com
About COYA 302
COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. COYA 302 comprises proprietary low dose interleukin-2 (LD IL-2) and CTLA-4 Ig and is being developed for subcutaneous administration for the treatment of patients with ALS and other neurodegenerative diseases. These mechanisms may have additive or synergistic effects.
Coya is currently conducting the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS ( Identifier: NCT07161999 ).
COYA 302 is an investigational product not yet approved by the FDA or any other regulatory agency.
Forward-Looking Statements
This press release contains "forward-looking" statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," and similar expressions are intended to identify forward-looking statements.
Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to market conditions; the satisfaction of customary closing conditions related to the private placement and other uncertainties related to the private placement; the anticipated use of proceeds from the private placement; risks associated with the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress and timing of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; our exploratory clinical signals may not be predictive of outcomes in larger, randomized controlled trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; anticipated interactions with the FDA under Fast Track designation; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.
We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260210471934/en/
Investor Contact
David Snyder, CFO
david@coyatherapeutics.com
astr partners
Matthew Beck
matthew.beck@astrpartners.com
917-415-1750
Media Contacts
Russo Partners
David Schull
David.Schull@russopartnersllc.com
858-717-2310
Rachelle Babb
rachelle.babb@russopartnersllc.com
929-325-7559
FAQ**
How does Coya Therapeutics Inc. COYA plan to address the gaps in the ALS treatment landscape as mentioned in the upcoming webinar?
2. What specific insights can Fred Grossman, D.O., FAPA, and the other physicians bring to the discussion regarding Coya Therapeutics Inc. COYA's approach to ALS?
3. How does the ALSTARS Phase 2 clinical trial aim to evaluate the efficacy of COYA 302 in comparison to existing ALS therapies?
4. What are the anticipated next steps for Coya Therapeutics Inc. COYA following the completion of the webinar and the ALSTARS trial?
**MWN-AI FAQ is based on asking OpenAI questions about Coya Therapeutics Inc. (NASDAQ: COYA).
NASDAQ: COYA
COYA Trading
1.31% G/L:
$4.265 Last:
20,188 Volume:
$4.23 Open:
